Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medtronic (MDT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

DUBLIN , May 19, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Looking at stock returns, Eli Lilly's 55% growth is much better than Medtronic's -16% change over the last twelve months.

Here's What Makes Medtronic Stock A Better Pick Over This Pharmaceuticals Company

AbbVie

CVS Health

General Dynamics

Iron Mountain

Coca-Cola

Mondelez

T-Mobile US

UnitedHealth Group

Bear markets are an inevitable if particularly unpleasant part of the market cycle. But investors who hold the best stocks to buy for bear markets can mitigate at least some of the damage.

The 10 Best Stocks for a Bear Market

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE DUBLIN and PARIS , May 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.

EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Medtronic's (MDT) Onyx Frontier DES is utilized to treat patients with CAD.

Medtronic's (MDT) Onyx Frontier DES Receives FDA Approval

Investors are optimistic about Medtronic's (MDT) rising market share gains and ongoing business recovery.

Here's Why Investors Should Retain Medtronic (MDT) Stock

The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN , May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier™ drug-eluting stent (DES). As the latest evolution in the Resolute DES family, Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx™ DES, with an enhanced delivery system1 designed to improve deliverability and increase acute performance2 in even the most challenging of cases.1 The Onyx Frontier DES is used for the treatment of patients with coronary artery disease (CAD), which is caused by plaque buildup on the inside of the coronary arteries.

Medtronic receives FDA approval for latest generation drug-eluting coronary stent system

Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio DUBLIN and MENLO PARK, Calif. , May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Intersect ENT, expanding the company's comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.

Medtronic completes acquisition of Intersect ENT

Since the start of fiscal 2022, Medtronic (MDT) has been witnessing a strong recovery and displayed a return to growth.

Medtronic (MDT) Global Business Gains Ground, Volume Woes Stay

Looking at stock returns, CVS's 18% growth is much better than Medtronic's -20% change over the last twelve months.

Is There A Better Pick Over Medtronic Stock?

Humana

These three stocks are leaders in their respective areas of the healthcare sector.

3 Top Healthcare Stocks to Buy for May

General Electric

DUBLIN and CHICAGO , April 28, 2022 /PRNewswire/ -- Providing excellent care inside and outside of the traditional hospital is the new normal for patients, clinicians, and payers seeking more choices without compromising excellent outcomes. Today, Medtronic and GE Healthcare announce a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs).

Medtronic and GE Healthcare announce a collaboration to meet growing need for outpatient care

CHICAGO & DUBLIN--(BUSINESS WIRE)--GE Healthcare, Medtronic announce collaboration focused on unique needs, demand for care at Ambulatory Surgery Centers(ASCs), Office Based Labs(OBLs)

GE Healthcare and Medtronic Announce a Collaboration to Meet Growing Need for Outpatient Care

Its entry into the booming robotic surgery space may unlock additional revenue.

Why Surgical Innovation Should Boost Medtronic's Growth

Dr. Laura Mauri will drive integration of medical and scientific intelligence and patient safety and engagement as chief scientific, medical and regulatory officer DUBLIN , April 25, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced that Laura Mauri, M.D., M.S.c. has been appointed Medtronic Chief Scientific, Medical and Regulatory Officer.

Medtronic names new chief scientific, medical, and regulatory officer

Medtronic is the world's largest medical device company - market cap is ~$145bn, and revenues will likely be >$3.3bn in FY22. The company also pays a dividend yielding 2.3% at the present time and its share price is ~20% discounted to recent highs.

Medtronic: Holding The Stock A Solid Decision Despite Diabetes Woes

In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.

Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays

Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.

Medtronic (MDT) Reports Positive Findings Backing RDN System

ABIOMED

Edwards Lifesciences

Intuitive Surgical

Stryker

Thermo Fisher Scientific

With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. The post 7 Medical Device Stocks to Buy as Covid-19 Fears Fade appeared first on InvestorPlace.

7 Medical Device Stocks to Buy as Covid-19 Fears Fade

Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the Symplicity renal denervation procedure Medtronic also completes enrollment in the SPYRAL HTN-ON MED trial DUBLIN and WASHINGTON , April 4, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial, which were presented today at the American College of Cardiology's 71st Annual Scientific Session (ACC.22) late-breaking featured clinical research sessions. The data were also simultaneously published in The Lancet .1 In the first 80 patients of the SPYRAL HTN-ON MED trial, the data demonstrated that patients who were prescribed anti-hypertensive medications and treated with the Medtronic Symplicity Spyral™ Renal Denervation (RDN) System continued to show durable, clinically significant blood pressure reductions through three years.

ACC.22: Medtronic renal denervation system demonstrates significant blood pressure reduction through three years

Doximity

Skylight Health Group

What's a break in the clouds due to the pandemic? Maybe the ease of meeting with your doctor.

3 Best Telemedicine Stocks for Investors

There are several reasons to consider buying Medtronic aside from its market-topping dividend.

Why It's Time to Buy This 1 Dividend Aristocrat

SYDNEY--(BUSINESS WIRE)--Medtronic Australasia, a subsidiary of Medtronic plc (NYSE:MDT) — a global leader in healthcare technology — has announced that New Zealand digital health innovators Alimetry and The Clinician were among the five winners in the inaugural Medtronic APAC Innovation Challenge (MAIC). Auckland-based Alimetry is a digital healthcare and medical device startup that develops breakthrough solutions for diagnosing disorders of gastrointestinal function. “We're very excited to wi

ANZ Innovators Alimetry and The Clinician Among Five Winners In Medtronic APAC Innovation Challenge

Medtronic's (MDT) TITAN 2 study will examine the safety and efficacy of the implantable TNM device in people with OAB.

News for Medtronic Stock (MDT)